Similar Papers

Paper Title
Journal
Date
Author
Real-world outcomes of first-line pembrolizumab plus pemetrexed-carboplatin for metastatic nonsquamous NSCLC at US oncology practices
Vamsidhar Velcheti ... Bilal Piperdi
Scientific Reports | VOL. 11
Vamsidhar Velcheti, et. al.Vamsidhar Velcheti ... Bilal Piperdi
28 Apr 2021
Outcomes of first-line pembrolizumab monotherapy for PD-L1–positive (TPS ≥50%) metastatic NSCLC at US oncology practices
Vamsidhar Velcheti
Video Journal of Biomedicine | VOL. -
Vamsidhar VelchetiVamsidhar Velcheti
14 Feb 2020
Cost effectiveness of first-line pemetrexed plus platinum compared with other regimens in the treatment of patients with nonsquamous non-small cell lung cancer in the US outpatient setting
Manan Shah ... Mark R Green
Lung Cancer | VOL. 82
Manan Shah, et. al.Manan Shah ... Mark R Green
07 Aug 2013
Health-Related Quality-of-Life Outcomes in Patients with Classical Hodgkin Lymphoma: A Prospective, Observational Study in US Oncology Practices
Jakub Svoboda ... Clara Chen
Blood | VOL. 134
Jakub Svoboda, et. al.Jakub Svoboda ... Clara Chen
13 Nov 2019
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Table of Contents
-
Annals of Oncology | VOL. 36
--
01 Jan 2025
Comments on The Study of Correlation Between Progression-Free and Overall Survival in Patients with Hodgkin Lymphoma
Yue-Can Zeng ... Yi Wang
Annals of Oncology | VOL. -
Yue-Can Zeng, et. al.Yue-Can Zeng ... Yi Wang
01 Jan 2025
Editorial Board
-
Annals of Oncology | VOL. 36
--
01 Jan 2025
89P Spatial analysis using MultiOmyx hyperplex assay reveals high prevalence of mature tertiary lymphoid structure (TLS) and PDL1 expression in the MSI-high colorectal carcinoma (CRC)
Q Au ... V Chizhevsky
Annals of Oncology | VOL. 35
Q Au, et. al.Q Au ... V Chizhevsky
01 Dec 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.